Lyka Labs Limited
Winner of India 500 SME Awards 2024
Lyka Labs Limited
Winner of India 500 SME Awards 2024
Details
Lyka Labs Limited
Public Limited Company
Pharmaceuticals
Manufacturer of Pharmaceutical Products.
1976
457
Bharuch
Ankleshwar - 393002
Gujarat
Introduction
Its WHO-GMP certified manufacturing facility in Ankleshwar, Gujarat, covers 36,000 sq. meters, with dedicated units for dry powder injections, topical preparations, lyophilized injections, and sterile APIs. The company employs over 450 people and 180 contract workers. Additionally, Lyka’s R&D center in Mumbai is approved by the Indian government and focuses on developing pharmaceuticals, cosmetics, and nutraceuticals.
Ipca Laboratories holds a 40.98% stake in Lyka Labs and supports its expansion, particularly in international markets. Lyka has a strong presence in dermatology and novel drug delivery systems (NDDS), continuously developing new products. The company exports lyophilized products to countries including Nigeria, Kenya, Peru, Sudan, and the Philippines, and is registering additional products in global markets.
Lyka has pioneered liposomal drug delivery systems using lyophilization technology, targeting enhanced drug delivery with reduced toxicity. Its product development pipeline includes therapies for atopic dermatitis, diabetic neuropathic pain, acne, and bacterial infections. The company’s Ankleshwar facility manufactures a broad range of formulations, including creams, ointments, and injections.
With strong international partnerships and a growing product portfolio, Lyka Labs is well-positioned for future growth in both domestic and global markets, focusing on lyophilized products, dermatology, and innovative drug delivery systems.
Director and CFO Details
Mr. Yogesh Babulal Shah
Commerce Graduate
Mr. Yogesh B. Shah, a Commerce Graduate with over 30 years of experience in accounting and finance, is the Director and CFO of Lyka Labs Ltd. He has served as Chief Financial Officer since July 2014 and was appointed as Executive Director on February 12, 2020. His extensive expertise has significantly contributed to the company’s financial management and strategic direction.
Established in 1976, Lyka Labs is a publicly listed pharmaceutical company specializing in pharmaceutical formulations and sterile active pharmaceutical ingredients (APIs). The company is recognized for its lyophilization expertise, producing high-quality freeze-dried formulations across various therapeutic areas, including anti-infective, anti-viral, antibiotics, and cardiovascular drugs.
Under Mr. Shah’s leadership, Lyka Labs has maintained a WHO-GMP certified facility in Ankleshwar, Gujarat, covering 36,000 sq. meters, with dedicated units for dry powder injections and sterile APIs. The company employs over 450 staff members and follows stringent quality standards.
Lyka’s R&D center in Mumbai, approved by the Indian government, focuses on developing pharmaceuticals and novel drug delivery systems (NDDS). Mr. Shah has been pivotal in driving international growth, with exports to countries like Nigeria, Kenya, and the Philippines, guiding Lyka Labs in expanding its global presence and product offerings while emphasizing innovation and sustained growth.
